The majority of patients with relapsed or refractory Hodgkin's lymphoma (HL) will not be cured with standard therapy. Relapse rates remain high even after autologous stem cell transplantation (SCT), particularly for patients with high-risk disease. Allogeneic SCT offers several potential advantages for patients with HL. It is feasible when autologous stem cells are not available and stem cell grafts will be tumor free. Perhaps a more important advantage is the potential to generate a graftversus-Hodgkin's lymphoma (GVHL) effect. Unfortunately, although allogeneic SCT may cure some HL patients, treatment-related mortality has been unusually high, and superior survival, when compared to autologous SCT, has not been demonstrated. Nonmyeloablative conditioning and allogeneic SCT may induce a direct GVHL reaction with less conditioning regimen-related toxicity and ultimately may have the potential to improve cure rates and survival for advanced HL patients. The success of allogeneic SCT in many cases is related not just to the intensive conditioning regimen, but also to the antitumor properties of the donor graft. This graft-versustumor (GVT) effect is independent of the high-dose conditioning therapy, and is mediated, at least in part, by donor T cells contained in the stem cell graft. In fact, the rationale for some of the first clinical attempts at SCT was based on the potential of allogeneic bone marrow to provide 'adoptive immunotherapy' and destroy leukemia cells surviving radiation therapy. The contribution of a GVT response has been studied extensively and is clearly documented in animal models of SCT.
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The contribution of a GVT response has been studied extensively and is clearly documented in animal models of SCT. [2] [3] [4] [5] Over the past decade, evidence has also accumulated for a potent GVT effect in human SCT. Initial evidence was based on several indirect although important clinical observations that included: (1) the abrupt withdrawal of immunosuppression (or a flare of acute graft-versus-hostdisease (GVHD)) re-established complete remission in some patients with relapsed acute leukemia; 6, 7 (2) the risk of leukemic relapse was higher for recipients of syngeneic marrow grafts than for recipients of allogeneic grafts; 8, 9 (3) GVHD after allogeneic bone marrow transplantation (BMT) was protective against relapse in some patient groups; 8, 10 and (4) T-cell depletion of an allogeneic donor graft resulted in an increased relapse risk, especially for patients with chronic myelogenous leukemia (CML). 8, 11 However, the use of donor leukocyte infusions (DLI) to treat relapse after allogeneic SCT provides the most direct evidence for a GVT reaction in humans. A total of 60-80% of patients with relapsed CML will achieve a complete molecular remission after infusion of unmanipulated donor leukocytes. [12] [13] [14] [15] [16] [17] The majority of DLI-induced remissions for CML are durable, and event-free survival rates are over 60-70%. [18] [19] [20] GVT activity is disease specific Unfortunately, not all patients develop a GVT effect after DLI. Responses are disease specific and results from various studies are shown in Table 1 . Response rates for patients with acute leukemia who relapse after allogeneic SCT are particularly disappointing and range between 0 and 29%. 13, 15 In one large retrospective study of acute lymphocytic leukemia (ALL) patients, long-term survival was estimated to be 13%. 21 In acute myelogenous leukemia (AML), chemotherapy before DLI may increase response rates, but even with this approach, 2-year survival rates are only 19%. 22 Nevertheless, for those patients who respond, remissions may be durable, 18 and 2-year survival for patients who achieve a complete remission has been estimated to be over 40%. 22 
Indirect evidence for GVHL effects
The evidence for a specific GVHL reaction (referred to as GVHL to avoid confusion with GVHD) was initially based on several indirect although important observations (Table 2) . First, there are several studies that suggest lower relapse rates after allogeneic BMT when compared to autologous BMT. Jones et al 23 initially reported significantly lower relapse rates after allogeneic marrow grafting than after autologous SCT in a subgroup of patients with chemotherapy-sensitive disease (18 vs 46%, P ¼ 0.02). This benefit appeared to be offset by the higher treatmentrelated mortality (TRM) associated with allogeneic transplantation when compared to autologous transplant (47 vs 21%, P ¼ 0.007), and an overall survival benefit was not identified. In a more recent analysis of a larger series of patients from the Hopkins group, allogeneic SCT continued to result in a trend toward lower relapse rates in patients with chemotherapy-sensitive disease (34 vs 51%, P ¼ 0.17); 24 the hazard ratio of 0.51 suggested a 2-fold increased risk of relapse after autologous SCT that did not reach statistical significance owing to the small numbers of patients studied. Data from the Seattle group further support the presence of a GVHL effect of allogeneic SCT. 25 In all, 68 recipients of autologous stem cell grafts were compared to 53 recipients of allogeneic grafts. Recipients of allogeneic stem cells were more likely to have high-risk features including more advanced disease (P ¼ 0.04), more prior therapy (P ¼ 0.005), higher disease stage (P ¼ 0.03), and marrow involvement (P ¼ 0.004). Nevertheless, this study showed a lower relapse rate after allogeneic marrow grafting (45 vs 76%, P ¼ 0.05). Again, the lower relapse rate seemed to be offset by a nonsignificant increase in nonrelapse mortality (53 vs 43%, P ¼ 0.2) and the overall event-free survival (EFS) was not different (26 vs 14%, P ¼ 0.6). Of particular interest, the frequency of relapse at previously uninvolved sites was similar in both groups, suggesting that relapse was not because of reinfused tumor cells. Therefore, the lower relapse rate after allogeneic stem cell grafting can be, at least partially, attributed to a GVHL effect.
Not all data demonstrate lower relapse rates after allogeneic SCT when compared to autologous SCT. 26 However, interpretation of all of these studies is limited by inclusion of only small numbers of patients and because it is difficult to directly compare recipients of autologous and allogeneic grafts. Specific patient characteristics and risk factors, as well as pretransplant conditioning and posttransplant care are likely to be different in patients undergoing autologous and allogeneic SCT. To overcome these limitations, an analysis from the European Group for Blood and Marrow Transplantation (EBMT) compared outcomes after allogeneic SCT in 45 patients with Hodgkin's lymphoma (HL) that were matched with 45 autologous SCT recipients. 27 Patients were matched for age, sex, disease status, conditioning regimen, and time from diagnosis to SCT. In this analysis, outcomes were comparable although in both groups a low rate of progression-free survival (15-24%) and a high rate of relapse (61%) were noted. The generally poor outcomes in this report can be partly accounted for by the high-risk characteristics of the patients studied; for instance, over half of the patients had chemotherapy refractory disease at the time of transplant. Nevertheless, this analysis did identify an association of grades II-IV acute GVHD with lower relapse rates after allogeneic SCT, lending additional support to the hypothesis that an allogeneic graft-versusHodgkin's disease effect can be generated.
Unfortunately, although it is clear that allogeneic SCT may cure some patients with HL who have no other treatment options, it is at the expense of unusually high TRM rates. This is highlighted in Table 3 ; mortality rates have ranged from 31 to 63% after allogeneic SCT for HL, Allogeneic SCT results in lower relapse rates compared to autologous SCT [23] [24] [25] Donor leukocyte infusions given as primary therapy can induce a direct graft-versus-Hodgkin's disease reaction 31, 35 Nonmyeloablative allogeneic SCT results in significant response rates in relapsed and refractory Hodgkin's disease 31, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] 81 while progression-free, event-free, and overall survival rates have been disappointing. [23] [24] [25] [27] [28] [29] [30] Several factors may account for the poor outcome in most reports. For instance, in the largest series from the International Bone Marrow Transplant Registry, 30 all patients were heavily pretreated, had advanced disease, and over half of the patients had a Karnofsky performance status of 80% or lower. A 61% TRM rate was noted and over half of the deaths resulted from respiratory complications. While there was no association of GVHD with relapse, the high TRM rate likely precluded identification of any GVHL activity. Most other single institution trials also included many heavily pretreated patients often with advanced or refractory disease. Therefore, while some patients may enjoy long-term disease-free survival, the role for conventional allogeneic SCT has been limited. Although most of the retrospective studies of allogeneic SCT for HL are difficult to interpret and include limited numbers of patients, they do suggest that if regimen-related toxicity could be minimized, allogeneic SCT may improve the outcome for patients with relapsed HL at least in part due to graftversus-lymphoma activity.
Direct evidence for GVHL effects
More direct evidence for an immunologic antilymphoma effect comes from attempts to induce a direct GVT reaction in patients with HL. For instance, donor leukocyte infusions have been given to several patients with HL both for relapse after allogeneic SCT and as primary GVT induction. Data on the use of DLI for relapse after allogeneic SCT are limited, presumably because of the small numbers of donor transplants performed for HL. In a large multicenter North American database that has collected both retrospective and prospective data on over 400 DLI recipients, only seven patients received DLI for HL. One patient was not evaluable, and two of the remaining six patients experienced partial responses sustained for over 6 and 18 months at last follow-up (R Collins, unpublished data).
DLI as primary therapy for relapsed HL
Additional direct evidence for GVHL activity is provided by studies using DLI as primary therapy for patients who have not had a prior allogeneic SCT. The rationale for this approach was based on the experience using DLI for relapsed leukemia after allogeneic SCT.
14 These studies suggested that HLA-matched donor leukocytes might induce a direct GVT reaction in patients without the need for prior allogeneic SCT. In our pilot studies, 31 we administered HLA-matched sibling donor leukocytes without the use of any conditioning therapy to determine (1) that using DLI as primary therapy would be safe; (2) if donor cells would survive and engraft in the host without additional therapy, and (3) if primary DLI could induce a direct GVT reaction. We speculated that donor chimerism would be a prerequisite for GVT induction, and therefore, this approach might be particularly useful in patients with HL. Since these patients typically have a life-long T-cell defect and are generally heavily treated, they are likely immunosuppressed prior to DLI, and donor chimerism could be anticipated without the need for conditioning therapy. This study included three patients with Hodgkin's disease in relapse after autologous SCT. One patient was not evaluable for response, one patient had a minor but significant antilymphoma response in the setting of grade II acute GVHD, and one patient achieved a complete remission sustained for over 2 years after the administration of primary DLI. This study provided one of the first demonstrations that a direct GVHL effect could be induced with HLA-matched donor lymphocytes. However, only the most heavily pretreated patients exhibited sustained donor chimerism or antitumor responses.
Nonmyeloablative allogeneic SCT for HL
Our data showed that donor cells could survive and induce a direct GVT reaction after primary DLI, but only in the most immunosuppressed patients. We reasoned, as did others, [32] [33] [34] that preinfusion immunosuppressive therapy would enhance engraftment and hence the likelihood of an antitumor response. Therefore, in our follow-up studies, we administered DLI-or G-CSF-stimulated allogeneic peripheral blood mononuclear cells after nonmyeloablative immunosuppressive conditioning. 35 Among the various patients treated were 11 patients with Hodgkin's disease relapsed after autologous SCT. Two of the 11 patients were not evaluable, while four achieved a sustained complete remission. An additional three patients had a partial and sustained response to this therapy. The conditioning therapy included low-dose cyclophosphamide and fludarabine, which would not be anticipated to have significant activity in relapsed or refractory HL, and it is very unlikely that the conditioning regimen accounted for this high rate of response. It is also notable that the majority of responding patients also developed GVHD. We believe that this represents direct evidence for a GVHL effect mediated by allogeneic donor cells.
These results are similar to data from other centers. The MD Anderson group reported on six heavily pretreated patients with Hodgkin's disease who had failed autologous SCT, and showed that nonmyeloablative allogeneic transplantation resulted in three complete remissions. 36 In an update of their data, 18 patients were treated with nonmyeloablative conditioning regimens and allogeneic SCT. Although three patients died of treatment-related causes, at least six patients were in remission with a median follow-up of 7 months (P Anderlini, personal communication).
Nonmyeloablative allogeneic SCT is performed with the intent of maximizing GVT activity in the setting of reduced conditioning regimen toxicity. This is particularly attractive in HL where TRM is prohibitively high after myeloablative allogeneic SCT. A number of other trials using this approach have included patients with HL as outlined in Table 4 . 31, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Although these various studies all use different conditioning regimens and include only small numbers of patients with HL, this approach results in significantly less treatment-related toxicity than a conventional allogeneic SCT, and has the potential for inducing a meaningful and potent GVHL reaction. It is important to note that many of the patients in these trials were heavily pretreated and had refractory disease, yet response rates varied from 25% to over 70%, and many patients experienced sustained complete remissions. In many cases, it is reasonable to assume that the conditioning regimen should have little impact on disease status, 35, 38 although in some trials, particularly those using an intensive, although nonablative regimen, 37, 42 it may be more difficult to separate the antitumor effects of the conditioning from the GVHL effects of the transplant.
Despite these encouraging results, TRM even after nonmyeloablative allogeneic SCT for HL has been significant, as shown in Table 4 . Most deaths, however, are related to GVHD and infection, and mortality from direct regimen-related toxicity has been low. Rates for TRM of 0-40% for patients with HL, and 6-36% for patients with a variety of diseases treated with multiple different regimens, seem reasonable given the high-risk patients enrolled on these trials. Many of these patients were multiply relapsed or had refractory disease, were of older age, or had undergone prior SCT; TRM from conventional allogeneic stem cell grafting in these patients would be anticipated to range between 25 and 85%.
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Sequential autologous and nonmyeloablative allogeneic SCT
Given these persuasive data for GVHL activity, Carella et al 42 performed a trial to maximize both the effects of high-dose chemotherapy and the immunologic potential of allogeneic SCT in patients with lymphoma. This study included 10 patients with HL who underwent high-dose chemotherapy and autologous stem cell rescue followed by nonmyeloablative conditioned allogeneic transplantation. 42 Five patients were in remission at the time of the report, and a sixth patient died in third remission. Although not direct evidence, this study does provide important support for a meaningful GVHL effect. It also suggests a novel approach to take advantage of the dose intensity provided with autologous SCT as well as the immunologic GVHL effects of allogeneic donor cell transplantation.
Future strategies for allogeneic cell therapy
Toxicity from conditioning, GVHD, and immunosuppression from both myeloablative and nonmyeloablative conditioned SCT remains significant and markedly limits application of allogeneic immunotherapy for HL. Several different approaches to limit toxicity and potentially improve outcomes after allogeneic cell therapy (ACT) are a TRM rates in some cases are inferred from the reported cause of death. b TRM rates in all patients with various diseases included in the study. c GVHD developed only after DLI. Flu, fludarabine; Cy, cyclophosphamide; TBI, total body irradiation; ATG, anti-thymocyte globulin; XRT, X-ray therapy; AraC, cytosine arabinoside; Ida, idarubicin; TRM, treatment-related mortality; NR, not reported; NA, not applicable; CR, complete remission.
outlined in Table 5 . Most strategies are either designed to minimize GVHD, enhance a GVT reaction, or improve on specificity of GVT activity.
Separation of GVHD and GVT Activity
Several nonspecific strategies that are not unique for HL attempt to separate GVT activity from GVHD. Promising approaches include the use of dose escalated DLI 49, 50 or depletion of effector cells from the donor product, such as CD8+ T cells, which are suspected of causing GVHD. 51, 52 Another method that might limit toxicity of ACT involves administration of irradiated (and hence inactivated) DLI; preliminary data suggest that irradiated donor T cells can retain GVT activity but cause minimal GVHD. 53 In vivo and ex vivo regulation of donor T cells
In some cases, nonspecific in vivo activation of donor T cells with interleukin-2 may enhance GVT activity. 54 Other methods that may limit GVHD in the setting of allogeneic immunotherapy include the administration of cytokines or growth factors to alter T-cell cytokine profiles or protect mucosal barriers. For instance, cytokines that result in the generation of Th2-type T cells may attenuate GVHD, 55 and cytokines such as IL-11 or keratinocyte growth factor may minimize GVHD by protection of mucosal barriers and subsequent cytokine release. [56] [57] [58] It may also be possible to enhance the antitumor properties of donor T cells through nonspecific but physiologic activation through ex vivo costimulation of donor T cells prior to DLI. 59 
Regulation of GVHD and GVT through genetic engineering of donor T cells
One of the more elegant strategies designed to attenuate GVHD without altering GVT reactivity has been the use of genetically modified donor T cells engineered to contain a 'suicide gene'. For instance, transduction of T cells with the herpes simplex thymidine kinase (HSV-TK) gene confers sensitivity to ganciclovir. 60, 61 These cells have been effective when administered as DLI to treat post-transplant lymphoproliferative disorders (PTLD), and subsequent GVHD was successfully treated with ganciclovir. This strategy is now being tested in larger clinical trials using DLI to treat relapsed disease after allogeneic BMT, and holds significant promise for all situations involving allogeneic cell therapy.
It may also be possible to alter genetically cytotoxic T cells to overcome direct inhibition from tumor cells. For instance, EBV-specific T cells can be inhibited by transforming growth factor-b (TGF-b) produced by HL cells. This inhibition can be overcome by transducing T cells with a defective, and hence dominant negative, TGF-b receptor effectively shielding them from inhibition. 62 In the future, genetic manipulation, not only of effector cells, but also of tumor cells and antigen-presenting cells, 63 may be an effective strategy for enhancing GVT activity against HL as well other tumors.
GVT induction with EBV-specific donor T cells
While the target antigens for GVT activity in general, and GVHL in particular, are not known, up to half of HL are associated with EBV, and it is intriguing to postulate that donor T cells may recognize EBV-specific antigens. Therefore, HL may respond to allogeneic antiviral-directed cell therapy that need not be 'tumor specific'. Several observations suggest that EBV antigens may be appropriate targets for cellular immunotherapy including (1) the majority of patients who develop EBV-associated PTLD after allogeneic SCT will achieve a complete remission after DLI; [64] [65] [66] (2) DLI has prevented PTLD after allogeneic SCT in highrisk patients; 67 (3) autologous EBV-specific cytotoxic T-cell infusions have been studied in patients with HL 68 and cytotoxic T cells with EBV specificity could be generated in the majority of cases, providing antiviral activity in vivo in some patients. Trials using allogeneic EBV-specific T cells as immunotherapy for HL also are under way at several centers. In one trial, EBV-specific CTLs are generated from matched or partially matched donors. At least one patient treated with refractory HL received partially matched unrelated donor EBV-specific CTL with no conditioning therapy and achieved a sustained partial response for over 6 months (K Lucas, personal communication). It is also notable, however, that in one trial of nonmyeloablative allogeneic SCT for HL, three patients achieved a complete remission; tissue specimens from two of these patients were tested for EBV and staining was negative in both. 36 Although it is not yet known if viral antigens mediate the allogeneic GVHL effects, this strategy has the potential to generate an antilymphoma reaction with little complication from the conditioning therapy or GVHD.
GVT induction with antigen-and tumor-specific donor T cells
Tumor-specific immunotherapy is the most direct, and perhaps the most promising approach to safer cellular therapy. Unfortunately, target antigens for GVT induction are largely unknown, although several possibilities other than EBV-associated antigens can be considered. Several tumor types express novel epitopes, such as bcr/abl in CML, that are attractive, although theoretical targets for tumor-specific immunotherapy. 69 Alternatively, in some cases, overexpressed or mutated forms of normal proteins Table 5 Novel approaches to allogeneic adoptive immunotherapy Minimize GVHD Low-dose DLI followed by dose escalation 49, 50 CD8+ cell depletion or CD4+ cell selection of DLI 51, 52 Irradiated or inactivated DLI 53 Transduction of suicide genes (ie HSV-TK) into donor T cells 60 Cytokines to generate Th-2-type T cells 55 Protect mucosal barriers (ie IL-11, KGF) [56] [57] [58] Enhance GVT activity Use of cytokines to modulate T-cell function and phenotype [54] [55] [56] [57] [58] Ex vivo activation through costimulation of donor T cells 59 Vaccination of donor to tumor-specific antigens 75 Genetic manipulation of tumor-reactive T cells 62 Generation of antigen-specific or tumor-specific donor T cells [70] [71] [72] [73] Administration of EBV-specific donor T cells to treat HL Graft-versus-Hodgkins disease DL Porter et al may be recognized as targets for donor cytotoxic T cells. One example is the overexpression of proteinase 3 in CML. Donor-derived cytotoxic T cells specific for proteinase 3 can be identified after allogeneic SCT and their presence correlates with improved outcome. 70, 71 Lineage-restricted minor histocompatibility (mH) antigens are other attractive targets that could result in GVT induction with minimal GVHD. 72, 73 It has been possible to generate mH antigenspecific cytotoxic T cells that effectively lyse leukemic blasts suggesting that they may be useful for adoptive immunotherapy. 74 Whether mH antigen-specific T cells will be useful for patients with HL remains to be determined.
An alternative method to generate tumor-specific donor T cells is through vaccination of the donor to known tumor antigens. Unfortunately, for most cancers, tumor-specific antigens have not been identified. One notable exception is in the case of myeloma where immunoglobulin idiotype can serve as a tumor antigen. Vaccination of a donor to patient myeloma-specific idiotype prior to BMT has resulted in transfer of idiotype-specific immunity in some cases. 75 It is notable that tumor-specific cytotoxic T cells have been generated and used as successful immunotherapy with minimal toxicity from GVHD in some patients with relapsed CML. 76 This example suggests that the paradigm of tumor-specific allogeneic cell therapy is possible in some cases, and ultimately may be feasible not only for CML but also for HL and for a variety of malignancies. These, and other novel trials, hold the greatest promise for improving the specificity, efficacy, and safety of allogeneic cell therapy.
Conclusions
While allogeneic SCT may cure some patients with HL, outcome is limited by unusually high TRM rates. Nevertheless, there does appear to be a significant allogeneic GVHL effect. Recently, several trials of nonmyeloablative allogeneic SCT have shown that a potent antilymphoma reaction can be generated with acceptable regimen-related toxicity. This approach is particularly attractive for patients with high-risk features who are anticipated to relapse after, or who have already failed autologous SCT. A number of approaches are being tested that are designed to minimize toxicity from GVHD or enhance the antitumor potential of allogeneic cell therapy. The role for novel strategies using tumor-specific (or viral-specific) allogeneic cell therapy in HL remains to be determined, although there is no doubt that identification of target antigens and effector cells for GVHL activity will lead to newer, more effective methods of immunotherapy for HL. It should be cautioned, however, that interpretation of the data for GVHL activity is hindered by the heterogeneous nature of the patients, conditioning regimens, and trial designs. The time is now right for randomized trials to compare autologous SCT to full or nonmyeloablative allogeneic SCT in patients with high-risk HL.
